KYMERA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
KYMERA THERAPEUTICS, INC. (KYMR) had Debt Securities, Available-for-sale, Amortized Cost of $1.39 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.39B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.41B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.26B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $864.28M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $1.39B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.41B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $1.26B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $864.28M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $626.98M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $685.58M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $732.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $798.37M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $636.88M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $653.19M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $326.91M 10-K · filed 2025-02-27 |
| 2023-09-30 | $356.21M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $423.59M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $468.78M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $496.04M 10-K · filed 2024-02-22 |
| 2022-09-30 | $445.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $409.55M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $492.77M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $520.29M 10-K · filed 2023-02-23 |
| 2021-09-30 | $454.40M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $319.51M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $382.10M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $427.86M 10-K · filed 2022-02-24 |
| 2020-09-30 | $426.88M 10-Q · filed 2020-11-05 |
| 2019-12-31 | $15.94M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |